Ofloxacin 400 mg Tablet: Indications, Contraindications, Off-Label Uses, and Drug Interactions
Ofloxacin 400 mg is FDA-approved for treating specific bacterial infections including community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated skin infections, gonorrhea, chlamydial infections, pelvic inflammatory disease, and urinary tract infections—but its use is now severely restricted due to widespread fluoroquinolone resistance, particularly for gonorrhea. 1
FDA-Approved Indications
Ofloxacin 400 mg tablets are indicated for mild to moderate infections caused by susceptible organisms 1:
Respiratory Infections
- Community-acquired pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae
- Acute bacterial exacerbations of chronic bronchitis (ABECB) due to H. influenzae or S. pneumoniae
- Critical caveat: Reserve ofloxacin for ABECB only when no alternative treatments exist, as fluoroquinolones carry serious adverse reaction risks 1
Skin and Soft Tissue
- Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis 1
Genitourinary Infections
- Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae 2, 1
- Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis 1
- Mixed infections of urethra/cervix due to C. trachomatis and N. gonorrhoeae 1
- Acute pelvic inflammatory disease (including severe) due to C. trachomatis and/or N. gonorrhoeae
- If anaerobes suspected, add appropriate anaerobic coverage 1
Urinary Tract Infections
- Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, E. coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa
- Reserve for patients with no alternatives due to serious adverse reaction profile 1
- Complicated UTIs due to E. coli, K. pneumoniae, P. mirabilis, C. diversus, or P. aeruginosa 1
- Prostatitis due to E. coli 1
Dosing for Approved Indications
The standard dose is 400 mg orally once or twice daily depending on infection severity, with treatment duration typically 7-10 days (except for single-dose gonorrhea treatment) 2, 1.
Contraindications
Ofloxacin is absolutely contraindicated in persons with hypersensitivity to ofloxacin or any quinolone antimicrobial agent. 1
Additional Critical Restrictions
- Pregnancy: Avoid due to teratogenic effects on bone and cartilage development 3
- Children and adolescents: Not approved for long-term use (>several weeks) due to concerns about effects on bone and cartilage growth, though may be considered for multidrug-resistant tuberculosis when no alternatives exist 3
Major Limitations and Resistance Concerns
Gonorrhea Treatment—No Longer Recommended
Ofloxacin should NOT be used for gonorrhea in most clinical scenarios due to widespread quinolone-resistant N. gonorrhoeae (QRNG). The 2006 CDC guidelines explicitly state 4:
- Quinolones are contraindicated for gonorrhea in:
- Men who have sex with men (MSM)
- Patients with recent foreign travel (especially Asia/Pacific)
- Partners with travel history
- Infections acquired in California or Hawaii
- Areas with increased QRNG prevalence
While historical data showed 98.6% cure rates for gonorrhea with ofloxacin 400 mg 2, resistance has rendered this obsolete. Current first-line therapy is ceftriaxone or cefixime 4.
Off-Label Uses
Drug-Resistant Tuberculosis
Ofloxacin has documented off-label use in multidrug-resistant tuberculosis (MDR-TB) when first-line agents cannot be used 3. However:
- Levofloxacin is preferred over ofloxacin due to better long-term safety data 3
- Cross-resistance exists among ciprofloxacin, ofloxacin, and levofloxacin 3
- Should not be used as first-line for drug-susceptible TB 3
Otitis Externa
Ofloxacin otic solution (0.3%) has demonstrated efficacy for otitis externa, though this is a different formulation than the 400 mg oral tablet 5.
Chronic Sinusitis and Otitis
High sinus concentrations and broad spectrum support use in chronic sinusitis and otitis when other treatments fail 6.
Drug Interactions
Divalent and Trivalent Cations—Critical Interaction
Antacids and medications containing divalent cations (Ca²⁺, Mg²⁺, Fe²⁺, Zn²⁺) or trivalent cations (Al³⁺, Fe³⁺) markedly decrease ofloxacin absorption. 3, 1
- Separate administration by at least 2 hours before or after ofloxacin 3
- Chelation potential follows this order: Fe³⁺ > Al³⁺ > Cu²⁺ > Ni²⁺ > Pb²⁺ > Zn²⁺ > Mg²⁺ > Ca²⁺ > Ba²⁺ 1
- Applies to: antacids, iron supplements, multivitamins with minerals, calcium supplements, sucralfate
Methylxanthines
Unlike some fluoroquinolones, ofloxacin has NO clinically significant interaction with theophylline or caffeine. 7 This distinguishes it from ciprofloxacin, which can increase theophylline levels.
Renal Impairment
- 80% excreted unchanged in urine 3
- Dose adjustment required when creatinine clearance <50 mL/min
- Not removed by hemodialysis; no supplemental dosing needed post-dialysis 3
Hepatic Disease
- Drug levels not significantly affected by liver disease 3
- Can be used with caution in severe hepatic disease, though increased monitoring recommended
Safety Profile
Common Adverse Events (from US clinical trials) 7:
- Nausea: 3.5%
- Insomnia: 1.8%
- Headache: 1.4%
- Dizziness: 1.2%
Serious Adverse Reactions
Fluoroquinolones as a class carry black box warnings for:
- Tendinitis and tendon rupture
- Peripheral neuropathy
- CNS effects (seizures, psychosis)
- Exacerbation of myasthenia gravis
- QT prolongation
Ofloxacin has lower photosensitivity and tendinitis rates compared to some other fluoroquinolones, but higher rates of certain neurological events. 8
Monitoring
- No crystalluria observed with ofloxacin 7
- Generally well-tolerated with rapidly reversible adverse effects 7
- Adverse reaction incidence does not increase with age 7
Clinical Pearls
Bioavailability: Ofloxacin has nearly 100% oral bioavailability, allowing seamless transition from IV to oral therapy without dose adjustment 8, 6.
Urinary concentrations: Achieves >600 mcg/mL in urine 2-4 hours post-dose (400 mg), well above MIC₉₀ for most uropathogens 9.
Prostatic penetration: Mean peak levels of 4.5 mcg/g in prostatic tissue, exceeding MIC₉₀ for most prostatic pathogens 9.
Resistance surveillance: Culture and susceptibility testing should be performed periodically during therapy, especially for P. aeruginosa infections, as resistance can develop rapidly 1.